SLFN11 and triple-negative breast carcinoma: Recent research from our group has found knock-out of SLFN11 in a prostate cell line did not cause resistance to olaparib nor did low SLFN11 levels in triple-negative breast cancer (TNBC)-rich cohort of PDX models [11].